Using incretin therapies in neuro, immunology
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock-full of numerous incretin therapies, the Big Pharma’s new strategy will be to test some of those drugs across neurology and immunology indications. “A new focus area first in 2025 will be to … Read more